How Analysts Feel About Galectin Therapeutics, Inc. (GALT) After Touching 52-Week High?

June 18, 2018 - By Hannah Black

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 1.86 in 2018 Q1. Its up 1.33, from 0.53 in 2017Q4. It improved, as 7 investors sold Galectin Therapeutics, Inc. shares while 7 reduced holdings. 17 funds opened positions while 9 raised stakes. 4.02 million shares or 30.74% more from 3.08 million shares in 2017Q4 were reported.
Northern Tru Corporation reported 0% stake. Art Advisors Ltd holds 57,775 shares. Benchmark Cap holds 0.83% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 221,700 shares. 14,144 were accumulated by Element Mgmt Limited Liability Corp. Optimum Investment invested in 20 shares or 0% of the stock. Buckingham Asset Mngmt Lc has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Lpl Fin Ltd Limited Liability Company holds 0% or 23,593 shares. Da Davidson Com accumulated 731,300 shares or 0.07% of the stock. 20,000 were reported by Jefferies Gp Limited Liability Company. Dynamic Advisor Solutions Limited Liability Corp has invested 0.01% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Tennessee-based Courage Cap Mngmt Lc has invested 0.11% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Verition Fund Management holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 10,195 shares. Geode Cap Mngmt Ltd Com stated it has 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Moreover, Manufacturers Life Ins The has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 192 shares. Wells Fargo Mn has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT).

Since January 25, 2018, it had 2 insider purchases, and 21 sales for $12.51 million activity. CZIRR JAMES C also sold $256,081 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, June 1. $572,021 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares were sold by Shlevin Harold H.. CALLICUTT JACK W sold $702,500 worth of stock or 120,000 shares. ZUCCONI THEODORE DANIEL had sold 4,000 shares worth $14,320. 100,000 shares were sold by TRABER PETER G, worth $751,000. $646,800 worth of stock was sold by 10X Fund – L.P. on Friday, June 8.

The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) hit a new 52-week high and has $9.58 target or 4.00 % above today’s $9.21 share price. The 6 months bullish chart indicates low risk for the $347.59 million company. The 1-year high was reported on Jun, 18 by Barchart.com. If the $9.58 price target is reached, the company will be worth $13.90M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.26% or $0.46 during the last trading session, reaching $9.21. About 2.70M shares traded or 286.00% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.97% since June 18, 2017 and is uptrending. It has outperformed by 65.40% the S&P500.

Analysts await Galectin Therapeutics, Inc. (NASDAQ:GALT) to report earnings on August, 13. They expect $-0.14 EPS, 0.00 % or $0.00 from last year’s $-0.14 per share. After $-0.12 actual EPS reported by Galectin Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Fool.com which released: “3 Biotech Stocks That Soared This Week: Are They Buys?” on June 16, 2018, also Globenewswire.com with their article: “Galectin Therapeutics Inc. Announces New CEO” published on June 12, 2018, Nasdaq.com published: “2 Clinical-Stage Biotech Stocks That Could Soar Next Week” on June 17, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Seekingalpha.com and their article: “Galectin Therapeutics’s Market Value Should Soar In The Coming Months” published on June 07, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” with publication date: June 13, 2018.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $347.59 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: